Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Platelets lacking PIP5KIγ have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion

Yanfeng Wang, Liang Zhao, Aae Suzuki, Lurong Lian, Sang H. Min, Ziqian Wang, Rustem I. Litvinov, Timothy J. Stalker, Tadayuki Yago, Arkadiusz G. Klopocki, David W. Schmidtke, Helen Yin, John K. Choi, Rodger P. McEver, John W. Weisel, John H. Hartwig, Charles S. Abrams

Blood (2013) 121 (14): 2743–2752.

https://doi.org/10.1182/blood-2012-07-445205

Published: 2013

Includes: Supplemental data

Journal Articles

RhoA Is Essential for Maintaining Normal Megakaryocyte Ploidy Distribution and Platelet Generation

Aae Suzuki, Jae-Won Shin, Ph.D., Yuhuan Wang, PhD, Mortimer Poncz, MD, John K. Choi, MD, PhD, Dennis E Discher, Ph.D., Christopher L. Carpenter, MD, PhD, Lurong Lian, Liang Zhao, Ph.D., Yanfeng Wang, Charles S. Abrams, MD

Blood (2012) 120 (21): 385.

https://doi.org/10.1182/blood.V120.21.385.385

Published: 2012

Journal Articles

A Phase I Study of Midostaurin (PKC412) Investigating Cardiac Interval Effects In Healthy Subjects

Adam del Corral, Catherine Dutreix, Alice Huntsman Labed, Sumita Rai, Kai Grosch, Joel Morganroth, Robert Harrell, Jr., Yanfeng Wang

Blood (2010) 116 (21): 4362.

https://doi.org/10.1182/blood.V116.21.4362.4362

Published: 2010

Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD

Blood (2009) 114 (22): 1127.

https://doi.org/10.1182/blood.V114.22.1127.1127

Published: 2009

Journal Articles

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Richard A. Larson, MD, Yen Lin Chia, PhD, Camille Granvil, PhD, François Guilhot, MD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Michele Baccarani, MD, Timothy P. Hughes, MD, MBBS, Jerry R. Nedelman, PhD, Yanfeng Wang, PhD

Blood (2009) 114 (22): 2213.

https://doi.org/10.1182/blood.V114.22.2213.2213

Published: 2009

Journal Articles

Platelets Lacking PIP5KIγ Have Impaired Cytoskeletal Dynamics and Adhesion, but No Defect in Integrin Activation.

Yanfeng Wang, Aae Suzuki, Lurong Lian, Rustem I. Litvinov, Timothy J. Stalker, John K. Choi, John W. Weisel, Lawrence F Brass, Charles S. Abrams

Blood (2009) 114 (22): 772.

https://doi.org/10.1182/blood.V114.22.772.772

Published: 2009

Journal Articles

Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis

Lurong Lian, Yanfeng Wang, Matthew Flick, John Choi, Edward W. Scott, Jay Degen, Mark A. Lemmon, Charles S. Abrams

Blood (2009) 113 (15): 3577–3584.

https://doi.org/10.1182/blood-2008-09-178913

Published: 2009

Journal Articles

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

François Guilhot, MD, Timothy P Hughes, MD, Jorge Cortes, MD, Yanfeng Wang, PhD, Michael Hayes, PhD, Anthony Gichangi, PhD, Brian J. Druker, MD, Michele Baccarani, MD

Blood (2008) 112 (11): 447.

https://doi.org/10.1182/blood.V112.11.447.447

Published: 2008

Journal Articles

Loss of Individual PIP5KI Isoforms Demonstrate That Spatial PIP2 Synthesis Is Required for Platelet Second Messenger Formation & Integrity of the Actin Cytoskeleton

Yanfeng Wang, M.D., Lurong Lian, M.D., Aae Suzuki, Rustem I. Litvinov, M.D., Timothy J. Stalker, Ph.D., Alec A. Schmaier, Lawrence F. Brass, MD, PhD, John Weisel, Ph.D., Charles S. Abrams, MD

Blood (2008) 112 (11): 109.

https://doi.org/10.1182/blood.V112.11.109.109

Published: 2008

Journal Articles

Impaired Actin Assembly and Lamellipodia Formation in ATE1 Knockout Platelets.

Lurong Lian, M.D., Anna S. Kashina, Ph.D., Karen P. Fong, Ph.D., Yanfeng Wang, M.D., Charles S. Abrams, MD

Blood (2008) 112 (11): 1834.

https://doi.org/10.1182/blood.V112.11.1834.1834

Published: 2008

Journal Articles

Platelets Lacking Both Pleckstrin and Pleckstrin-2 Have a Marked Deficient Cell Spreading and Actin Assembly

Yanfeng Wang, M.D., Lurong Lian, M.D., John H. Hartwig, PhD, Charles S. Abrams, MD

Blood (2008) 112 (11): 253.

https://doi.org/10.1182/blood.V112.11.253.253

Published: 2008

Journal Articles

Effects of Imatinib on the Pharmacokinetics of Acetaminophen in Korean Patients with Chronic Myelogenous Leukemia (CML)

Dong-Wook Kim, MD, PhD, Sa-Hee Park, Yu Jin, MS, Michael Hayes, PhD, Yanfeng Wang, PhD

Blood (2008) 112 (11): 5056.

https://doi.org/10.1182/blood.V112.11.5056.5056

Published: 2008

Journal Articles

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O'Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang

Blood (2008) 111 (8): 4022–4028.

https://doi.org/10.1182/blood-2007-10-116475

Published: 2008

Includes: Supplemental data

Journal Articles

Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Richard A. Larson, MD, Brian J. Druker, MD, Francois Guilhot, MD, Stephen G. O’Brien, MD, PhD, Tillman Krahnke, Insa Gathmann, Yanfeng Wang

Blood (2007) 110 (11): 1935.

https://doi.org/10.1182/blood.V110.11.1935.1935

Published: 2007

Journal Articles

Mice Lacking Pleckstrin or Pleckstrin-2 Each Have Unique Platelet Secretion Defects.

Yanfeng Wang, M.D., Lurong Lian, M.D., Matthew Flick, Ph.D., Jay Degen, Ph.D., Mark Lemmon, Ph.D., Charles S. Abrams, MD

Blood (2007) 110 (11): 134.

https://doi.org/10.1182/blood.V110.11.134.134

Published: 2007

Journal Articles

PIP5KIγ Knockout Megakaryocytes Have Defects in Their Cytoskeleton & Demarcation Membrane System, yet Form Proplatlets & Platelets.

Yanfeng Wang, MD, Rustem Litvinov, Ph.D., John W. Weisel, Ph.D., John H. Hartwig, Ph.D., Charles S. Abrams, M.D.

Blood (2006) 108 (11): 1793.

https://doi.org/10.1182/blood.V108.11.1793.1793

Published: 2006

Journal Articles

Loss of PIP5KIβ Causes a Defect in Lamellipodia Formation and Shear Resistant Adhesion.

Xinsheng Chen, PhD, Yanfeng Wang, M.D., Edward K. Williamson, Ph.D., Timothy J. Stalker, Ph.D., Lawrence F. Brass, M.D., Ph.D., Morris J. Birnbaum, M.D., Ph.D., John H. Harwig, Ph.D., Charles S. Abrams, M.D.

Blood (2006) 108 (11): 141.

https://doi.org/10.1182/blood.V108.11.141.141

Published: 2006

Journal Articles

Knockout of the PKC Substrate Pleckstrin Causes Pleomorphic Defects in Platelets, Lymphocytes and Granulocytes.

Lurong Lian, MD, Yanfeng Wang, M.D., Xinsheng Chen, Ph.D., Tami Bach, M.D., Ph.D., Laurie Lenox, Ph.D., Peimin Zhu, Ph.D., Matthew Flick, Ph.D., Edward Scott, Ph.D., Jay Degen, Ph.D., Bruce Freedman, Ph.D., Gary Koretzky, M.D., Ph.D, Mark Lemmon, Ph.D., Charles S. Abrams, M.D.

Blood (2006) 108 (11): 394.

https://doi.org/10.1182/blood.V108.11.394.394

Published: 2006

Journal Articles

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Richard A. Larson, MD, Brian J. Druker, MD, Francois Guilhot, MD, Stephen G. O’Brien, MBChB, PhD, Insa Gathmann, MS, Gilles J. Riviere, PhD, Charlene So, PharmD, Yanfeng Wang, PhD, on Behalf of the IRIS Study Group

Blood (2006) 108 (11): 429.

https://doi.org/10.1182/blood.V108.11.429.429

Published: 2006

Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP

Blood (2006) 108 (11): 4820.

https://doi.org/10.1182/blood.V108.11.4820.4820

Published: 2006

NARROW

Platelets lacking PIP5KIγ have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion

RhoA Is Essential for Maintaining Normal Megakaryocyte Ploidy Distribution and Platelet Generation

A Phase I Study of Midostaurin (PKC412) Investigating Cardiac Interval Effects In Healthy Subjects

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Platelets Lacking PIP5KIγ Have Impaired Cytoskeletal Dynamics and Adhesion, but No Defect in Integrin Activation.

Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

Loss of Individual PIP5KI Isoforms Demonstrate That Spatial PIP2 Synthesis Is Required for Platelet Second Messenger Formation & Integrity of the Actin Cytoskeleton

Impaired Actin Assembly and Lamellipodia Formation in ATE1 Knockout Platelets.

Platelets Lacking Both Pleckstrin and Pleckstrin-2 Have a Marked Deficient Cell Spreading and Actin Assembly

Effects of Imatinib on the Pharmacokinetics of Acetaminophen in Korean Patients with Chronic Myelogenous Leukemia (CML)

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Mice Lacking Pleckstrin or Pleckstrin-2 Each Have Unique Platelet Secretion Defects.

PIP5KIγ Knockout Megakaryocytes Have Defects in Their Cytoskeleton & Demarcation Membrane System, yet Form Proplatlets & Platelets.

Loss of PIP5KIβ Causes a Defect in Lamellipodia Formation and Shear Resistant Adhesion.

Knockout of the PKC Substrate Pleckstrin Causes Pleomorphic Defects in Platelets, Lymphocytes and Granulocytes.

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only